Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00887627 · ClinicalTrials.gov registry record · Phase 1
Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function
A Phase 1 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00887627 is a Phase 1 study that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT00887627, a Phase 1 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
A study to compare a conivaptan PK in subjects with mild or moderate kidney function impairment to subjects with normal kidney function after a 48-hour continuous infusion of conivaptan.
Interventions
- DRUG conivaptan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00887627
The ClinicalTrials.gov registry entry for NCT00887627 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which conivaptan hydrochloride is the first listed.
NCT00887627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00887627 about?
NCT00887627 is a clinical study titled "Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function". A study to compare a conivaptan PK in subjects with mild or moderate kidney function impairment to subjects with normal kidney function after a 48-hour continuous infusion of conivaptan.
What is the current status of trial NCT00887627?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2009-04. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00887627?
The interventions under investigation include: conivaptan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00887627?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.